
# PROSTATE CANCER 2018

April 28, 2018 | Omni Shoreham Hotel | Washington, DC



## **COURSE DIRECTORS**

George K. Philips, MBBS, MD, MPH
MedStar Georgetown University Hospital
MedStar Washington Hospital Center
Georgetown Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, DC

Ross E. Krasnow, MD, MPH MedStar Washington Hospital Center Washington, DC

## **CO-COURSE DIRECTORS**

Young Kwok, MD

University of Maryland Medical Center University of Maryland School of Medicine Baltimore, MD **Filipe Carvalho, MD, PhD**MedStar Georgetown University Hospital Washington, DC



#### COURSE DIRECTORS

#### George K. Philips, MBBS, MD, MPH

Staff Physician, Hematology/Oncology MedStar Georgetown University Hospital MedStar Washington Hospital Center Georgetown Lombardi Comprehensive Cancer Center Professor and Vice Chair, Medicine Georgetown University School of Medicine Washington, DC

#### Ross E. Krasnow, MD, MPH

Staff Physician, Urologic Oncology MedStar Washington Hospital Center Washington, DC

## **CO-COURSE DIRECTORS**

#### Young Kwok, MD

Maryland Proton Treatment Center University of Maryland Medical Center Associate Professor, Radiation Oncology University of Maryland School of Medicine Baltimore, MD

#### Filipe Carvalho, MD, PhD

Resident, Urology MedStar Georgetown University Hospital Washington, DC

### **FACULTY**

#### **KEYNOTE SPEAKER**

#### Leonard G. Gomella, MD

President, Society of Urologic Oncology
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Senior Director, Clinical Affairs
Sidney Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA

#### Jeanny B. Aragon-Ching, MD

Clinical Program Director Genitourinary Cancers Inova Schar Cancer Institute Fairfax, VA Associate Professor, Medicine Virginia Commonwealth University Richmond, VA

#### Sonia E. Bellfield, MSN, RN, OCN

Clinical Research Nurse Coordinator National Cancer Institute Bethesda, MD

#### Michael A. Carducci, MD

AEGON Professor, Prostate Cancer Research Associate Cancer Center Director Clinical Research Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, MD

#### Peter L. Choyke, MD

Senior Investigator Chief, Molecular Imaging Program National Cancer Institute Bethesda, MD

#### Amin Herati, MD

Director, Male Infertility and Men's Health Johns Hopkins Hospital Assistant Professor, Urology James Buchanan Brady Urological Institute Baltimore, MD

#### Arif Hussain, MD

Professor, Medicine Pathology and Biochemistry University of Maryland School of Medicine Baltimore, MD

#### Jonathan J. Hwang, MD

Chair, Department of Ūrology MedStar Washington Hospital Center Associate Professor, Urology Georgetown University School of Medicine Washington, DC

#### William B. Isaacs, PhD

Professor, Oncology and Urology Johns Hopkins University School of Medicine Baltimore, MD

#### Adeel Kaiser, MD

Assistant Professor, Radiation Oncology University of Maryland School of Medicine Baltimore, MD

#### Jianqing Lin, MD

Co-Program Leader, GU Oncology GW Cancer Center Associate Professor, Medicine George Washington School of Medicine & Health Sciences Washington, DC

#### John H. Lynch, MD

Chairman, Ūrology MedStar Georgetown University Hospital Georgetown University School of Medicine Washington, DC

#### Ravi A. Madan, MD

Clinical Director Genitourinary Malignancies Branch National Cancer Institute Bethesda, MD

#### Howard L. Parnes, MD

Chief, Prostate and Urologic Cancer Research Group National Cancer Institute Bethesda, MD

#### Peter A. Pinto, MD

Director, Urologic Oncology Fellowship Program Head, Prostate Cancer Section Investigator, Urologic Oncology Branch National Cancer Institute Bethesda, MD

#### Kathryn L. Taylor, PhD

Professor, Oncology Georgetown University Medical Center Lombardi Comprehensive Cancer Center Washington, DC

#### Quoc-Dien Trinh, MD

Co-Director, Dana-Farber/Brigham and Women's Prostate Cancer Center Assistant Professor, Surgery Harvard Medical School Boston, MA

| Λ |    |   | м |    | Λ |
|---|----|---|---|----|---|
| Δ | (- | ы | N | I) | Δ |
|   |    |   |   |    |   |

| 7:00 AM            | Registration and Continental Breakfast   |         | ADVANCED PROSTATE CANCER eanny B. Aragon-Ching, MD; Filipe Carvalho, MD, PhD                          |
|--------------------|--|---------|---|
|                    | Welcome and Introduction  John H. Lynch, MD  EARLY STAGE PROSTATE CANCER                         | 1:00 PM | Biochemical Recurrence: Illuminating the Black Box Arif Hussain, MD                                   |
| 7:40 AM            | Two Decades of Prostate Cancer Prevention Research: Lessons Learned and Future                   | 1:25 PM | Current Status of Intensifying Up-front<br>Therapy for Metastatic Prostate Cancer<br>Jianqing Lin, MD |
|                    | <b>Directions</b> Howard L. Parnes, MD   | 1:50 PM | <b>Advances in Immunotherapy Applications</b> <i>Ravi A. Madan, MD</i>                                |
| 8:05 AM            | Treatment Decision Making and Quality of<br>Life Among Men Undergoing<br>Active Surveillance     | 2:15 PM | Castration Resistant Prostate Cancer<br>Michael A. Carducci, MD                                       |
| 8:25 AM            | Kathryn L. Taylor, PhD  Novel Diagnostic Imaging Modalities for                                  | 2:40 PM | Molecular Genetics and Biology of<br>Prostate Cancer<br>William B. Isaacs, PhD                        |
|                    | Localized Prostate Cancer Peter A. Pinto, MD   | 3:05 PM | Advances in Imaging of Prostate Cancer<br>Peter L. Choyke, MD   |
| 8:50 AM            | Focal Therapy Quoc-Dien Trinh, MD  | 3:30 PM | <b>Toxicity Management of Immunotherapy</b> <i>Sonia E. Bellfield, RN, MSN, OCN</i>                   |
| 9:25 AM<br>9:45 AM | Break and Visit the Exhibits  Radiation Therapy: New Technologies and                            | 3:50 PM | Panel Discussion  |
| 9.43 AIVI          | Future Directions  Adeel Kaiser, MD  | 4:00 PM | Closing Remarks<br>George K. Phillips, MBBS, MD, MPH  |
| 10:10 AM           | The Role for Prostatectomy in High Risk<br>Prostate Cancer<br>Quoc-Dien Trinh, MD                | 4:05 PM | Adjourn   |
| 10:35 AM           | Testosterone Replacement Therapy in Prostate Cancer Amin Herati, MD                              |         |   |
| 11:00 AM           | Panel Discussion   |         |   |
| 11:15 AM           | <b>KEYNOTE LECTURE Prostate Cancer Genomics and Inherited Risk</b> <i>Leonard G. Gomella, MD</i> |         |   |
| 12:15 PM           | Lunch and Visit the Exhibits   |         |   |

#### REGISTRATION INFORMATION

| Registration Fees:          |       |
|-----------------------------|-------|
| Physician                   | \$150 |
| Resident/Fellow             | \$50  |
| Advanced Practice Clinician | \$75  |
| Nurse                       | \$75  |
| Allied Health Professional  | \$75  |

## **Online Registration Preferred**

Please visit our secure website at https://CME.MedStarHealth.org/PROSTATE for updated program and registration information. We are unable to accept registrations or cancellations by telephone. If you wish to pay your registration fee by check, please download and print a registration form and mail it to the address on the registration form with your check.

All registrations will be confirmed by email only. Please use an email address that you check regularly. If you have questions regarding registration or do not receive an email confirmation of your registration within 1-2 business days, please contact us at **medstarcme@gmail.com** or **202-780-1656**.

## **Cancellation Policy**

Cancellations made in writing by **March 16, 2018** will be subject to a 50% penalty. No refunds will be given after **March 16, 2018**. Cancellations will not be accepted by telephone. In the unlikely event that the course is cancelled, MedStar Health will refund the registration fee, but is not responsible for any travel costs. Please note registration fees are non-transferable.

Please call **202-780-1656** or email **medstarcme@gmail.com** if you have any questions or need any additional information.

## **VENUE INFORMATION**

## Omni Shoreham Hotel 2500 Calvert St NW Washington, DC 20008

## **Special Assistance**

MedStar Georgetown University Hospital wishes to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently from other individuals because of the absence of auxiliary aids or services identified in the Americans with Disabilities Act. Please email **medstarcme@gmail.com** to notify us of your needs.



#### CME INFORMATION

## **Course Description**

#### Register today for the only multidisciplinary prostate cancer conference in the region!

This one-day educational experience will examine recent advances in the diagnosis and treatment of patients with localized and metastatic prostate cancer. Expert faculty will deliver state-of-the-art lectures that will include treatment approaches, clinical trials, and future directions. Attendees will have ample time to network with leaders in the field, participate in panel discussions and navigate complicated cases. Key clinical tops will include the use of biomarkers and advanced imaging in the diagnosis and treatment of early stage prostate cancer as well as advances in the multidisciplinary management of patients with high-risk, locally advanced and metastatic prostate cancer. Applications of new therapeutic agents, cutting edge radiation technology and evolving minimally invasive urologic surgical approaches will also be discussed. In addition, recommendations on resources for patients and practicing healthcare providers will be shared including specialized centers of excellence and the Genitourinary Multidisciplinary DC Regional Oncology Project (GUMDROP).

## **Learning Objectives**

- Interpret the role of prostate MRIs in developing treatment strategies for organ-confined prostate cancer
- Distinguish the proper use of early chemohormonal therapy in patients with high-risk and metastatic prostate cancer
- Differentiate intermediate and high-risk patients who will benefit from chemotherapy
- Examine prostate biomarkers in planning treatment for organ-confined prostate cancer
- Recognize intermediate and high-risk patients who will benefit from brachytherapy
- Assess the latest guidelines of the National Comprehensive Cancer Network (NCCN)
- Identify intermediate and high-risk patients who will benefit from immunotherapy
- Recognize intermediate and high-risk patients who will benefit from salvage therapy
- Illustrate the benefits of genetic testing for risk stratification in organ-confined prostate cancer
- Distinguish intermediate and high-risk patients who will benefit from testosterone replacement

## **Target Audience**

This conference is intended for urologists, radiation and medical oncologists, oncologic surgeons, residents, fellows, nurse practitioners, physician assistants, nurses, and other allied healthcare professionals interested in the treatment and management of prostate cancer.

## **Accreditation**



In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


## **Credit Designation**



This activity was planned by and for the healthcare team, and learners will receive 7.25 Continuing Education (IPCE) credits for learning and change

## PROSTATE CANCER 2018

April 28, 2018 | Omni Shoreham Hotel | Washington, DC



| FIRST NAME        | MIDDLE INITIAL                | LAST NAME |                   | SUFFIX |
|-------------------|-------------------------------|-----------|-------------------|--------|
| DEGREE            | HOSPITAL/COMPANY/ORGANIZATION |           |                   |        |
| MEDICAL SPECIALTY |                               |           |                   |        |
| ADDRESS           | STREET                        |           | SUITE OR APT#     |        |
| CITY              | STATE                         |           | ZIP / POSTAL CODE |        |
| TELEPHONE         | FAX                           |           |                   |        |
| E-MAIL            |                               |           |                   |        |

## □\$150 Physician Resident/Fellow □\$50 Advanced Practice Clinician □\$75 Nurse □ \$75 Allied Health Professional **\$75 Industry Professional** □\$300 ☐ Check Enclosed (Please make checks payable to "MSH - PROSTATE") Credit Card (Please indicate type below. Charges on statement will appear as "CMEQT") American Express ☐ Visa ☐ Mastercard CARD NUMBER \*CCV NUMBER EXPIRATION DATE (MO/YEAR) NAME OF CARDHOLDER CARDHOLDER SIGNATURE \*The CCV number is a 3-digit non-raised number printed on the back of the credit card in the right hand corner of the signature strip. Amex card CCV numbers are 4-digits long and are on the front of the card.

#### THREE WAYS TO REGISTER:

#### ■ ON THE WEB:

CME.MedStarHealth.org/PROSTATE

#### BY EMAIL:

Scan form and email to: MedStarCME@gmail.com

#### BY MAIL:

MSH - PROSTATE 3007 Tilden Street, NW, Suite 3N Washington, DC 20008

We are unable to accept registrations or cancellations by telephone.

All registrations will be confirmed by email only. Please use an email address that you check regularly. If you have questions regarding registration or do not receive an email confirmation of your registration within 1-2 business days, please contact us at MedStarCME@gmail.com or 202-780-1656.

#### **CANCELLATION POLICY:**

Cancellations made in writing by March 16, 2018 will be subject to a 50% penalty. No refunds will be given after March 16, 2018. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs.

Please call 202-780-1656 or email MedStarCME@gmail.com if you have any questions or need any additional information.

